Market Overview - U.S. stocks experienced a decline on Wednesday, with the Nasdaq dropping over 75 points, or 0.3%, closing at 22,497.85. The Dow Jones Industrial Average fell 0.37% to 46,121.28, while the S&P 500 eased 0.3% to 6,637.97 [1] Notable Stock Movements - **Alibaba Group Holding Ltd.**: The stock surged by 8.19%, closing at $176.44, with an intraday high of $180.16 and a low of $162.80. The 52-week range is $80.06 to $180.16. This rise followed CEO Eddie Wu's announcement of plans to expand the company's $53 billion investment in AI infrastructure [1][2] - **Intel Corp.**: Shares climbed 6.41% to close at $31.22, reaching a high of $31.70 and a low of $29.23. The stock's 52-week range is $17.67 to $32.38. The increase was driven by reports of Intel seeking an investment from Apple Inc., with discussions still in preliminary stages [3] - **UniQure N.V.**: The stock skyrocketed by 247.73%, closing at $47.50, with a high of $51.21 and a low of $37.12. The 52-week range is $4.45 to $51.21. This dramatic rise followed the announcement of positive results from its Phase I/II study of AMT-130 for Huntington's Disease, indicating significant slowing of disease progression [4] - **Tesla Inc.**: The stock increased by 3.98%, closing at $442.79, with an intraday high of $444.21 and a low of $429.03. The 52-week range is $212.11 to $488.54. Tesla secured a patent for its upcoming Cybercab, part of its innovative unboxed production process [5] - **Opendoor Technologies Inc.**: Shares jumped 16.24% to $8.23, with a high of $8.48 and a low of $7.31. The 52-week range is $0.51 to $10.87. In after-hours trading, the stock rose 10.3% to $9.08, following Jane Street Group's disclosure of a 5.9% stake in the company, boosting investor confidence [6]

Market Overview - The market experienced a decline following Fed Chair Jerome Powell's speech, which highlighted market uncertainty and stagflation [1] - Major indices closed lower, with the S&P 500 and Nasdaq both down 0.3%, the Dow Jones Industrial Average down 0.4%, and the Russell 2000 down 0.9% after reaching a 52-week high [2] Sector Performance - The oil and energy sectors emerged as the best performers, with the Energy Select Sector SPDR Fund (XLE) gaining 1.3% [2][7] - Gold prices dipped 1.5% after a rally, although analysts expect prices to continue climbing [3] Consumer Spending and Economic Indicators - A Bank of America report indicated that total debit and credit card spending per household has increased in recent months [4][7] - There was a reported surge in new house sales, but economists dismissed it as a fluke [4] Notable Stock Movements - Lithium Americas (LAC) saw a stock increase of 95.5%, while Tesla gained 4% due to analyst confidence [4] - uniQure, a gene therapy company, experienced a significant stock surge of 247.8% following positive results from its AMT-130 study for Huntington's disease [10] Noteworthy Stocks - Stocks with notable gains included Xcel Energy Inc (+6.7%), Intel Corp (+6.4%), Centene Corp (+5.8%), Mosaic Co (+4.3%), and CF Industries Holdings Inc (+5.7%) [8] - Conversely, the worst-performing stocks included Freeport-McMoRan Inc (-16.9%), Axon Enterprise Inc (-10.2%), and KKR & Co Inc (-6.3%) [12]

Skip to Main Content This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. These Stocks Moved the Most Today: Alibaba, Micron, Lithium Americas, Freeport-McMoRan, uniQure, and More By Joe Woelfel, Elsa Ohlen, Mackenzie Tatananni and Connor Smith Share Resize Reprints Continue ...

Uniqure (QURE) stock soared nearly 300% on Wednesday after the Dutch biotechnology company announced a major breakthrough in Huntington’s disease. Investors are cheering QURE shares this morning because the Nasdaq-listed firm has secured new financing worth $175 million from Hercules Capital as well. More News from Barchart QURE stock is now trading roughly 460% above its year-to-date low in early April. www.barchart.com Why Did the Clinical Data Light a Fire Under QURE Stock? Uniqure shares are rall ...

Company Highlights - Cidara Therapeutics Inc. (CDTX) reached a 52-week high of $87.19 as it advances its development plan for CD388, a non-vaccine preventive treatment for seasonal influenza, with enrollment in a Phase 3 study expected to start by September 2025 targeting 6,000 participants [1] - Maze Therapeutics Inc. (MAZE) saw its stock rise to a 52-week high of $27.09 following positive Phase 1 clinical results for MZE782, an oral therapy for Phenylketonuria and chronic kidney disease, with plans to enter Phase 2 studies in 2026 [3][4] - Medpace Holdings Inc. (MEDP) is set to report Q3 2025 financial results on October 22, 2025, and has raised its full-year guidance twice, indicating strong operational momentum, with the stock hitting a 52-week high of $506.55 [5][6] - Monopar Therapeutics Inc. (MNPR) rebounded from potential Nasdaq delisting to a 52-week high of $73.75, planning to seek approval for ALXN1840 for Wilson disease in early 2026, supported by long-term clinical data [7][8] - Prenetics Global Limited (PRE) projects 2025 revenue between $85 million and $100 million, a significant increase from $30.6 million in 2024, with its new wellness brand IM8 Health on track for $100 million in annual recurring revenue [9][10] - Protagonist Therapeutics Inc. (PTGX) is nearing a major milestone with Icotrokinra for psoriasis, having submitted a regulatory application to the FDA and EMA in July 2025, with the stock reaching a 52-week high of $66.70 [11][12] - uniQure N.V. (QURE) announced positive results from its Phase I/II study of AMT-130 for Huntington's disease, planning to submit a Biologics License Application in Q1 2026, with the stock soaring over 200% to a 52-week high of $51.21 [13][14] - Rezolute Inc. (RZLT) surged to a 52-week high of $9.02 ahead of topline results from its pivotal Phase III trial for hypoglycemia treatment, expected in December [15][16] - United Therapeutics Corp. (UTHR) reached a 52-week high of $442.01 as anticipation builds for data from the TETON-2 study of nebulized Tyvaso in idiopathic pulmonary fibrosis, with positive results reported earlier [17][18]

U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 100 points on Wednesday.The Dow traded down 0.35% to 46,129.26 while the NASDAQ fell 0.47% to 22,468.39. The S&P 500 also fell, dropping, 0.40% to 6,630.54.Check This Out: Top 2 Tech Stocks That May Plunge This MonthLeading and Lagging SectorsEnergy shares jumped by 1.9% on Wednesday.In trading on Tuesday, materials stocks fell by 1.5%.Top HeadlineCrude oil inventories in the U.S. declined by 0.607 million barrels i ...

Economic Indicators - Weekly initial unemployment claims are expected to increase by +2,000 to 233,000 [1] - August core capital goods new orders are expected to slip -0.1% month-over-month [1] - Q2 GDP is expected to remain unrevised at +3.3% quarter-over-quarter annualized [1] - August existing home sales are expected to fall -1.3% month-over-month to 3.96 million [1] - August personal spending is expected to rise by +0.5% month-over-month, and personal income is expected to rise by +0.3% month-over-month [1] - August core PCE price index is expected to rise by +0.2% month-over-month and +2.9% year-over-year [1] - University of Michigan's September US consumer sentiment index is expected to remain unchanged at 55.4 [1] Corporate Earnings - More than 22% of S&P 500 companies provided guidance for Q3 earnings that are expected to beat analysts' expectations, the highest in a year [2] - S&P companies are expected to post +6.9% earnings growth in Q3, up from +6.7% at the end of May [2] Housing Market - US August new home sales unexpectedly jumped +20.5% month-over-month to a 3.5-year high of 800,000, against expectations of a decline to 650,000 [2] Stock Market Movements - Chip stocks are climbing, led by a +5% jump in Intel after Nvidia's acquisition of a stake in Intel [10] - Energy producers are moving higher with WTI crude oil prices up more than +1%, benefiting companies like Diamondback Energy and Devon Energy [12] - uniQure NV is up more than +190% after reporting positive trial results for its Huntington's disease treatment [13] - General Motors is up more than +2% after UBS upgraded the stock to buy from neutral [15] - Freeport-McMoRan is down more than 10% after declaring force majeure on copper supplies [16]

智通财经APP获悉，周三，uniQure(QURE.US)暴涨超186%，创四年新高，报39.11美元。消息面上，9 月24日，该公司宣布与Hercules Capital达成1.75亿美元非稀释性高级担保定期贷款协议，包括现有5000 万美元债务再融资，额外1.25亿美元融资可提取，利息率降至9.70%，显著改善财务灵活性。此外，该 公司公布AMT-130在亨廷顿病1/2期关键研究中达到主要终点，高剂量组36个月数据显示疾病进展减缓 75%cUHDRS测量，同时关键次要终点TFC测量显示疾病进展减缓60%。 ...

周三，uniQure(QURE.US)暴涨超186%，创四年新高，报39.11美元。消息面上，9月24日，该公司宣布 与Hercules Capital达成1.75亿美元非稀释性高级担保定期贷款协议，包括现有5000万美元债务再融资， 额外1.25亿美元融资可提取，利息率降至9.70%，显著改善财务灵活性。此外，该公司公布AMT-130在 亨廷顿病1/2期关键研究中达到主要终点，高剂量组36个月数据显示疾病进展减缓75%cUHDRS测量，同 时关键次要终点TFC测量显示疾病进展减缓60%。 ...

The markets this week will focus on any fresh trade or tariff news. Later today, Aug new home sales are expected to decline by -0.3% m/m to 650,000. On Thursday, weekly initial unemployment claims are expected to increase by +2,000 to 233,000. Also, Aug core (ex-defense and aircraft) capital goods new orders are expected to slip -0.1% m/m. In addition, Q2 GDP is expected to be unrevised at +3.3% (q/q annualized). Finally, Aug existing home sales are expected to fall -1.3% m/m to 3.96 million. On Friday, Aug ...